Clinical trials: Lymphomas,
Immunodeficiency, Immunosuppression
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce…
- Conditions
- Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease
- Trial name
- NCT05655546
- Testing
- Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- Scripps Translational Science Institute
Lymphoma
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
The goal of this clinical research study is to find out how well the drug Zolinza (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat…
- Trial name
- NCT00787527
- Testing
- Zolinza (vorinostat), Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme (WHO Grade IV), Anaplastic Astrocytoma (WHO Grade III)
Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy
Cure rates for patients with high grade glioma remain disappointing, in part because tumor cells are often resistant to chemotherapy, and because using higher doses of chemotherapy causes damage to normal blood cells.
- Trial name
- NCT00272870
- Testing
- 06Benzylguanine, MGMT P140K, Meltenyi CliniMacs
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Moderate and Severe Haemophilia
HEAD-US SCORING SYSTEM: Assessment of the Real-world Impact of Ultrasound
Ultrasound represents a promising technique for the assessment of joint health in persons with haemophilia (PWH) by non-imaging specialists.
- Trial name
- NCT03237273
- Testing
- HEAD-US scoring system
- Volunteers
- 200 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
The purpose of this study is to learn the effects of brentuximab vedotin (SGN-35), an investigational medication, on patients with cutaneous T cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS).
- Conditions
- Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma, Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides
- Trial name
- NCT01396070
- Testing
- Brentuximab vedotin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Youn Kim
Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL)
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
This is a phase II, prospective clinical study to evaluate the efficacy and safety of Orelabrutinib combined with Low-Dose Radiotherapy or Rituximab in the treatment of Ocular Adnexal MALT Lymphoma
- Trial name
- NCT07247383
- Testing
- Orelabrutinib (ICP-022), radiotherapy, Rituximab (R)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hematologic Diseases, Acute Leukemia in Remission
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of…
- Conditions
- Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase
- Trial name
- NCT03842696
- Testing
- Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine)
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hodgkin Lymphoma
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
This is a multicenter, single-arm phase II study to evaluate the efficacy and safety of CS1001 monotherapy for relapsed/refractory classical Hodgkin Lymphoma (rr-cHL)
- Trial name
- NCT03505996
- Testing
- CS1001
- Where
- China
- Volunteers
- 82 people
- Sponsor
- CStone Pharmaceuticals
Lymphoma, Non-Hodgkin
GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
The purpose of this study is to evaluate the overall response rate of Obinutuzumab (GA101) in combination with Pixantrone in patients with relapsed aggressive B-cell lymphoma.
- Trial name
- NCT02499003
- Testing
- Obinutuzumab and Pixantrone
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Johannes Gutenberg University Mainz
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT07082686
- Testing
- ICP-248
- Where
- 29 sites in China
- Volunteers
- 75 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Tumor Lysis Syndrome
Elitek (Rasburicase) Immuno-Monitoring Study
Primary Objective: To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma…
- Trial name
- NCT01097369
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Sanofi
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of alisertib and bortezomib when given together with rituximab in treating patients with mantle cell lymphoma or B-cell low grade non-Hodgkin lymphoma that has returned…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
- Trial name
- NCT01695941
- Testing
- Alisertib, Bortezomib, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
The primary purpose of this study is to assess the safety and tolerability of ociperlimab (BGB-A1217) in combination with tislelizumab (BGB-A317) or rituximab in participants with relapsed or refractory (R/R) diffuse large B cell…
- Trial name
- NCT05267054
- Testing
- Ociperlimab, Tislelizumab, Rituximab
- Where
- 19 sites in China
- Volunteers
- 53 people
- Sponsor
- BeiGene
EBV-associated Lymphomas
KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial
The main purpose of this study is to determine the tolerability and feasibility of KSD-101 in patients with EBV-associated haematologic neoplasms,to observe the characteristics of dose-limiting toxicity (DLT)and to explore the…
- Trial name
- NCT05882305
- Testing
- Autologous monocyte-derived DCs pulsed withEBV-associated antigen
- Where
- China
- Sponsor
- Kousai Bio Co., Ltd.
Hodgkin Disease, Lymphoma, Non-Hodgkin
Tissue Collection for Studies of Lymph Cancer
Background: Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphomatoid Granulomatosis
- Trial name
- NCT01676805
- Where
- 2 sites in United States, Jamaica
- Volunteers
- 1,295 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia (ALL)
A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL
This research is being done to determine if allopurinol can change the metabolism of the oral chemotherapeutic medication 6-mercaptopurine (6-MP) in children with acute lymphoblastic leukemia (ALL).
- Trial name
- NCT02046694
- Testing
- Allopurinol
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Hodgkin's Lymphoma
Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
The current standard treatment for non-Hodgkin's lymphoma involves drugs called cyclophosphamide, doxorubicin, vincristine, prednisone and rituxan in a regimen called "R-CHOP." Using R-CHOP therapy, complete disappearance of…
- Trial name
- NCT00184002
- Testing
- Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Southern California
Relapsed Cutaneous T Cell Lymphom
Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas
To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with relapsed cutaneous T cell lymphomasell
- Trial name
- NCT02597153
- Testing
- Mitoxantrone HCL Liposome Injection
- Where
- China
- Volunteers
- 1 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
This phase I/II trial studies the side effects, best dose, and effectiveness of copanlisib and venetoclax in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT04939272
- Testing
- Copanlisib Hydrochloride, Venetoclax
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Lymphoma
SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002495
- Testing
- doxorubicin hydrochloride, vinblastine, standard subtotal nodal irradiation
- Where
- 22 sites in United States
- Volunteers
- 348 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.